Skip to main content

Table 1 Clinical and biochemical characteristics of included patients

From: Adult-onset autoimmune diabetes: comparative analysis of classical and latent presentation

  T1DM (n = 46) LADA (n = 46) p
Females, n (%) 23 (50.0%) 24 (52.2%) 0.835
Age at diabetes diagnosis, median (IQR) 38 (15) 42 (15) 0.057
Months between diagnosis of diabetes and insulin therapy beginning, median (IQR) 0 (0.0) 48 (56.3) < 0.001*
Months between diagnosis of diabetes and diagnosis of autoimmune aetiology, median (IQR) 0 (3.0) 60 (92.3) < 0.001*
Diabetes duration at the last follow-up, years, median (IQR) 8.0 (7.5) 11.0 (10.5) 0.023*
At the diagnosis of diabetes
 Symptoms at presentation, n (%) 40 (87.0%) 21 (45.7%) < 0.001**
 Diabetic ketoacidosis, n 2 0  
 Polyuric/polydipsic syndrome, n 38 21  
At the measurement of diabetes-related autoantibodies
 BMI (kg/m2), mean (± SD) 24.1 (± 3.8) 26.1 (± 5.2) 0.042***
 A1C (%), mean (± SD) 10.3 (± 2.4) 9.5 (± 2.2) 0.113
 C-peptide (ng/mL), median (IQR) 0.7 (0.6) 1.0 (1.4) 0.152
 Number of positive antibodies, median (IQR) 2 (2.0) 1 (1.0) 0.013*
 Patients with > 1 positive antibody, n (%) 31 (67.4%) 19 (41.3%) 0.012**
 Positive GADA, n/total (%) 43/46 (93.5%) 39/46 (84.8%) 0.180
 GADA title of patients with positive GADA (U/mL), median (IQR) 21.4 (94.1) 11.9 (60.4) 0.229
 Positive ICA, n/total (%) 30/43 (69.8%) 23/38 (60.5%) 0.383
 Positive IA2, n/total (%) 17/43 (39.5%) 10/45 (22.2%) 0.078
 IA2 title of patients with positive IA2 (U/mL), median (IQR) 10.5 (31.1) 4.1 (10.8) 0.093
 Positive IAA, n/total (%) 4/38 (10.5%) 1/35 (2.9%) 0.359
  1. * Independent-samples Mann–Whitney test
  2. ** Chi square test
  3. *** Independent-samples T-test